ARQT · Company research
Arcutis Biotherapeutics, Inc. Common Stock (ARQT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
25records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Why Is Arcutis Biotherapeutics Stock Surging Thursday? - Benzinga | Why Is Arcutis Biotherapeutics Stock Surging Thursday? Benzinga | View source ↗ | Benzinga | Oct 15, 2026 | neutral | 0 | 0.6 |
| Arcutis stock wins new Overweight at Cantor (ARQT:NASDAQ) - Seeking Alpha | Arcutis stock wins new Overweight at Cantor (ARQT:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 15, 2026 | neutral | 0 | 0.6 |
| Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts - Yahoo Finance | Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| ZORYVE Data May Change The Case For Arcutis Biotherapeutics (ARQT) - Simply Wall Street | ZORYVE Data May Change The Case For Arcutis Biotherapeutics (ARQT) Simply Wall Street | View source ↗ | Simply Wall Street | Oct 11, 2026 | neutral | 0 | 0.6 |
| Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, News, Quote & History - Yahoo! Finance Canada | Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 11, 2026 | neutral | 0 | 0.6 |
| Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts - Yahoo! Finance Canada | Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 11, 2026 | neutral | 0 | 0.6 |
| Arcutis Biotherapeutics (ARQT) Showcased Fresh ZORYVE Data, Is It Still 28% Below Fair Value? - Yahoo Finance | Arcutis Biotherapeutics (ARQT) Showcased Fresh ZORYVE Data, Is It Still 28% Below Fair Value? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 10, 2026 | neutral | 0 | 0.6 |
| Caregivers reported at least 25% less itch within 10 minutes for 46.6% of infants - Stock Titan | Caregivers reported at least 25% less itch within 10 minutes for 46.6% of infants Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical | Arcutis Biotherapeutics presented clinical data for ZORYVE (roflumilast) across multiple inflammatory skin conditions at major dermatology conferences. The INTEGUMENT-INFANT trial showed the drug was well-tolerated in infants aged 3-24 months with atopic dermatitis, with 34.4% achieving disease clearance at 4 weeks. Additional analyses demonstrated ZORYVE's efficacy in treating psoriasis on special sites including the scalp and genitals, with improvements in sexual function and quality of life. Real-world research highlighted concerns about long-term topical corticosteroid use, including skin thinning and systemic side effects, positioning ZORYVE as a potential alternative therapy. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical | Arcutis Biotherapeutics presented clinical data for ZORYVE (roflumilast) across multiple inflammatory skin conditions at major dermatology conferences. The INTEGUMENT-INFANT trial showed the drug was well-tolerated in infants aged 3-24 months with atopic dermatitis, with 34.4% achieving disease clearance at 4 weeks. Additional analyses demonstrated ZORYVE's efficacy in treating psoriasis on special sites including the scalp and genitals, with improvements in sexual function and quality of life. Real-world research highlighted concerns about long-term topical corticosteroid use, including skin thinning and systemic side effects, positioning ZORYVE as a potential alternative therapy. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bullish | 1 | 1 |
| Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts - Yahoo Finance | Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Arcutis Biotherapeutics: An Emerging GARP Stock (NASDAQ:ARQT) - Seeking Alpha | Arcutis Biotherapeutics: An Emerging GARP Stock (NASDAQ:ARQT) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 6, 2026 | neutral | 0 | 0.6 |
| An iShares ETF has an interest above 5% in Arcutis (ARQT), where BlackRock reports a passive stake. - Stock Titan | An iShares ETF has an interest above 5% in Arcutis (ARQT), where BlackRock reports a passive stake. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Arcutis Biotherapeutics announced the grant of 62,500 restricted stock units (RSUs) to six newly hired employees as a material inducement for employment. The RSUs will vest over four years with 25% vesting annually, subject to continued employment. The grants were approved by the Compensation Committee under the company's 2022 Inducement Plan. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | neutral | 0 | 1 |
| Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study | Merck announced that its investigational drug tulisokibart met the primary endpoint in a phase IIb study for moderate to severe hidradenitis suppurativa. High-dose and medium-dose regimens demonstrated superiority over placebo, with 72% and 64% of patients achieving HiSCR50 response respectively, compared to 35% for placebo. The drug also showed improvements in quality of life measures. Merck plans to advance tulisokibart into phase III development for HS and is evaluating it across six immune-mediated indications. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.25 | 1 |
| Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study | Merck announced that its investigational drug tulisokibart met the primary endpoint in a phase IIb study for moderate to severe hidradenitis suppurativa. High-dose and medium-dose regimens demonstrated superiority over placebo, with 72% and 64% of patients achieving HiSCR50 response respectively, compared to 35% for placebo. The drug also showed improvements in quality of life measures. Merck plans to advance tulisokibart into phase III development for HS and is evaluating it across six immune-mediated indications. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.25 | 1 |
| Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth and Improving Fundamentals - ChartMill | Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth and Improving Fundamentals ChartMill | View source ↗ | ChartMill | Oct 1, 2026 | neutral | 0 | 0.6 |
| Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last? - Yahoo Finance | Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 17, 2026 | neutral | 0 | 0.6 |
| Is Arcutis Biotherapeutics (ARQT) Stock Too Rich To Stay Reasonable? - Simply Wall Street | Is Arcutis Biotherapeutics (ARQT) Stock Too Rich To Stay Reasonable? Simply Wall Street | View source ↗ | Simply Wall Street | Aug 27, 2026 | neutral | 0 | 0.6 |
| Arcutis (NASDAQ: ARQT) insider plans $956K share sale - Stock Titan | Arcutis (NASDAQ: ARQT) insider plans $956K share sale Stock Titan | View source ↗ | Stock Titan | Aug 27, 2026 | neutral | 0 | 0.6 |
| Arcutis Biotherapeutics (ARQT) Stock Profit Turn Faces ZORYVE Concentration Question - Simply Wall Street | Arcutis Biotherapeutics (ARQT) Stock Profit Turn Faces ZORYVE Concentration Question Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| Arcutis Biotherapeutics (ARQT) Heads Into Earnings With Its ZORYVE Story Still Shaping Valuation - Yahoo Finance | Arcutis Biotherapeutics (ARQT) Heads Into Earnings With Its ZORYVE Story Still Shaping Valuation Yahoo Finance | View source ↗ | Yahoo Finance | Jul 30, 2026 | neutral | 0 | 0.6 |
| Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup - ChartMill | Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup ChartMill | View source ↗ | ChartMill | Jul 17, 2026 | neutral | 0 | 0.6 |
| ARQT Forecast — Price Target — Prediction for 2027 - TradingView | ARQT Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| ARCUTIS BIOTHERAPEUTICS ($ARQT) Releases Q1 2026 Earnings - Quiver Quantitative | ARCUTIS BIOTHERAPEUTICS ($ARQT) Releases Q1 2026 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | May 6, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.